FDA Works to Reduce the Spread of Misinformation
The U.S. Food and Drug Administration (FDA) recently issues a press release to help address and reduce the spread of misinformation. The FDA has taken steps to update its draft guidance titled, “Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers.”
From the FDA: “Specifically, the revised draft guidance, Addressing Misinformation About Medical Devices and Prescription Drugs Questions and Answers, sets out a policy that supports companies that issue certain kinds of internet-based communications (“tailored responsive communications”) to address internet-based misinformation about or related to their approved/cleared medical products when that misinformation is created or disseminated by an independent third party.”
View the FDA's recent press release.
Suggested For You

regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval

regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices

regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals

regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
regulatory intelligence
June 26th, 2024
New Details on Diversity Action Plans Provided by the US FDA
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

perspectives
July 9th, 2024
Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives
July 2nd, 2024
Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives
October 27th, 2020
FDA Advisory Committee Meeting Held to Discuss Important Topics Surrounding COVID-19 Vaccines